Filing Flows

Filing Flows › Akebia Therapeutics (AKBA) › Next earnings date

Akebia Therapeutics (AKBA) earnings: missed the estimate

Akebia Therapeutics (AKBA) reported on Nov 5, 2026 and missed the EPS estimate: −$0.05 against −$0.03 (-56.7%). Revenue was $36.9M for Q3 2026, -37% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result−56.7% vs estimate
Beat rate40%

The last report

Akebia Therapeutics reported revenue of $36.9M for the third quarter 2026 (-37% Y/Y), net loss $14.4M: Product revenue, net $34.8M, License, collaboration and other revenue $2.1M. How it makes money → · Every quarter →

Akebia Therapeutics: EPS against the estimate, last 5 reportsAkebia Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.01$0.00Nov 25−$0.06−$0.05Feb 26−$0.02−$0.03May 26−$0.03−$0.03Aug 26−$0.03−$0.05Nov 26
Latest (Nov 26): Estimate −$0.03, Reported −$0.05.

Akebia Therapeutics' latest quarter

Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Akebia Therapeutics beat earnings?

Akebia Therapeutics (AKBA) reported on Nov 5, 2026 and missed the EPS estimate: −$0.05 against −$0.03 (-56.7%).

When does AKBA report earnings?

The next date is not set yet.

Does Akebia Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.